Drug intelligence / Profile preview

MAR005

Development stage: Unknown
Lead developer: Marea Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

MAR005 is a monoclonal antibody developed by Marea Therapeutics for the treatment of hypertriglyceridaemia and related cardiometabolic disorders. It specifically targets and inhibits Angiopoietin-like 3 (ANGPTL3), a protein that regulates lipid metabolism by inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL). By blocking ANGPTL3, MAR005 promotes the clearance of triglyceride-rich lipoproteins and lowers plasma levels of triglycerides, LDL cholesterol, and other atherogenic lipids. The drug is currently being evaluated in Phase 1b clinical trials to assess its safety, pharmacokinetics, and lipid-lowering efficacy in patients with elevated triglycerides.

Targets

ANGPTL3 (Angiopoietin-like protein 3)

Beyond the preview

Go deeper on MAR005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAR005.

Explore the full profile